CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $4.77 Average Price Target from Brokerages

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has received a consensus rating of "Moderate Buy" from the five brokerages that are currently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $4.77.

Several research analysts have recently issued reports on the company. Piper Sandler began coverage on CytomX Therapeutics in a research note on Monday, April 14th. They issued an "overweight" rating and a $2.50 price objective for the company. Wedbush reissued an "outperform" rating and issued a $5.00 price objective on shares of CytomX Therapeutics in a research note on Friday, March 7th. StockNews.com initiated coverage on CytomX Therapeutics in a report on Tuesday, April 15th. They set a "hold" rating on the stock. Finally, HC Wainwright restated a "neutral" rating on shares of CytomX Therapeutics in a research report on Friday, March 7th.

CytomX Therapeutics Stock Performance

Shares of CytomX Therapeutics stock traded down $0.04 during midday trading on Thursday, hitting $0.66. 901,362 shares of the company traded hands, compared to its average volume of 2,692,713. The firm's fifty day moving average price is $0.63 and its 200-day moving average price is $0.87. The stock has a market cap of $53.19 million, a price-to-earnings ratio of 3.94 and a beta of 1.34. CytomX Therapeutics has a 12 month low of $0.40 and a 12 month high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last posted its earnings results on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.45. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The firm had revenue of $38.09 million for the quarter, compared to analysts' expectations of $13.53 million. Equities research analysts forecast that CytomX Therapeutics will post -0.05 earnings per share for the current year.

Hedge Funds Weigh In On CytomX Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Northern Trust Corp lifted its position in shares of CytomX Therapeutics by 16.0% during the fourth quarter. Northern Trust Corp now owns 150,632 shares of the biotechnology company's stock valued at $155,000 after purchasing an additional 20,746 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of CytomX Therapeutics by 1.5% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,547,215 shares of the biotechnology company's stock worth $1,594,000 after buying an additional 23,139 shares in the last quarter. Miller Financial Services LLC bought a new position in shares of CytomX Therapeutics in the fourth quarter valued at approximately $26,000. Prudential Financial Inc. increased its position in shares of CytomX Therapeutics by 76.2% during the fourth quarter. Prudential Financial Inc. now owns 64,300 shares of the biotechnology company's stock valued at $66,000 after acquiring an additional 27,800 shares during the last quarter. Finally, Traphagen Investment Advisors LLC purchased a new position in CytomX Therapeutics in the fourth quarter worth $31,000. 67.77% of the stock is owned by hedge funds and other institutional investors.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.